Healthcare company Abbott has announced the US launch of a device designed to provide treatment for people living with chronic pain.
The IonicRF Generator has been cleared by the US Food and Drug Administration to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system.
The Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain.
It is the first Abbott-developed radiofrequency ablation device and is also currently approved in Europe.
Keith Boettiger, vice president of neuromodulation at Abbott, said: “Most people who are candidates for radiofrequency ablation have tried other therapies such as medications and injections with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication.
“We are proud to be able to provide the first Abbott-designed radiofrequency ablation device, engineered to deliver safe and effective pain management. This is another example of our focus on widening the breadth of our neuromodulation portfolio and keeping patients central to everything we do at Abbott.”
